The Experts below are selected from a list of 1809 Experts worldwide ranked by ideXlab platform

Claudio Anasetti - One of the best experts on this subject based on the ideXlab platform.

  • Direction and magnitude of change in TOL group vs. non-TOL and control: Genes with decreased expression in TOL group.
    2015
    Co-Authors: Joseph Pidala, Gregory C. Bloom, Steven Eschrich, Minnie Sarwal, Steve Enkemann, Brian C. Betts, Francisca Beato, Sean Yoder, Claudio Anasetti
    Abstract:

    *TLR4—toll-like receptor 4; TLR8—toll-like receptor 8; PELI2—pellino homolog 2; IRAK3—interleukin-1 receptor-associated kinase 3; LILRA2—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2; LILRA5—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5; PDLIM5—PDZ and LIM domain 5; ARRB1—Arrestin, Beta 1; PAK1—p21 protein (Cdc42/Rac)-activated kinase 1; SOCS2—suppressor of cytokine signaling 2; RHOA—ras homolog gene family, member A; IL-13RA—interleukin 13 receptor, alpha 1; TNFSF13B—tumor necrosis factor (ligand) superfamily, member 13b (BAFF); TNFSF12—tumor necrosis factor (ligand) superfamily, member 12 (APRIL); GSN—gelsolin; SMAD1—SMAD family member 1; VNN1—vanin 1; PPT1—palmitoyl-protein thioesterase 1; SOD2—superoxide dismutase 2, mitochondrial; DAPK1—death-associated protein kinase 1; EVI5—ecotropic viral integration site 5; CCNY—cyclin Y.

Joseph Pidala - One of the best experts on this subject based on the ideXlab platform.

  • Direction and magnitude of change in TOL group vs. non-TOL and control: Genes with decreased expression in TOL group.
    2015
    Co-Authors: Joseph Pidala, Gregory C. Bloom, Steven Eschrich, Minnie Sarwal, Steve Enkemann, Brian C. Betts, Francisca Beato, Sean Yoder, Claudio Anasetti
    Abstract:

    *TLR4—toll-like receptor 4; TLR8—toll-like receptor 8; PELI2—pellino homolog 2; IRAK3—interleukin-1 receptor-associated kinase 3; LILRA2—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2; LILRA5—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5; PDLIM5—PDZ and LIM domain 5; ARRB1—Arrestin, Beta 1; PAK1—p21 protein (Cdc42/Rac)-activated kinase 1; SOCS2—suppressor of cytokine signaling 2; RHOA—ras homolog gene family, member A; IL-13RA—interleukin 13 receptor, alpha 1; TNFSF13B—tumor necrosis factor (ligand) superfamily, member 13b (BAFF); TNFSF12—tumor necrosis factor (ligand) superfamily, member 12 (APRIL); GSN—gelsolin; SMAD1—SMAD family member 1; VNN1—vanin 1; PPT1—palmitoyl-protein thioesterase 1; SOD2—superoxide dismutase 2, mitochondrial; DAPK1—death-associated protein kinase 1; EVI5—ecotropic viral integration site 5; CCNY—cyclin Y.

Gregory C. Bloom - One of the best experts on this subject based on the ideXlab platform.

  • Direction and magnitude of change in TOL group vs. non-TOL and control: Genes with decreased expression in TOL group.
    2015
    Co-Authors: Joseph Pidala, Gregory C. Bloom, Steven Eschrich, Minnie Sarwal, Steve Enkemann, Brian C. Betts, Francisca Beato, Sean Yoder, Claudio Anasetti
    Abstract:

    *TLR4—toll-like receptor 4; TLR8—toll-like receptor 8; PELI2—pellino homolog 2; IRAK3—interleukin-1 receptor-associated kinase 3; LILRA2—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2; LILRA5—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5; PDLIM5—PDZ and LIM domain 5; ARRB1—Arrestin, Beta 1; PAK1—p21 protein (Cdc42/Rac)-activated kinase 1; SOCS2—suppressor of cytokine signaling 2; RHOA—ras homolog gene family, member A; IL-13RA—interleukin 13 receptor, alpha 1; TNFSF13B—tumor necrosis factor (ligand) superfamily, member 13b (BAFF); TNFSF12—tumor necrosis factor (ligand) superfamily, member 12 (APRIL); GSN—gelsolin; SMAD1—SMAD family member 1; VNN1—vanin 1; PPT1—palmitoyl-protein thioesterase 1; SOD2—superoxide dismutase 2, mitochondrial; DAPK1—death-associated protein kinase 1; EVI5—ecotropic viral integration site 5; CCNY—cyclin Y.

Steven Eschrich - One of the best experts on this subject based on the ideXlab platform.

  • Direction and magnitude of change in TOL group vs. non-TOL and control: Genes with decreased expression in TOL group.
    2015
    Co-Authors: Joseph Pidala, Gregory C. Bloom, Steven Eschrich, Minnie Sarwal, Steve Enkemann, Brian C. Betts, Francisca Beato, Sean Yoder, Claudio Anasetti
    Abstract:

    *TLR4—toll-like receptor 4; TLR8—toll-like receptor 8; PELI2—pellino homolog 2; IRAK3—interleukin-1 receptor-associated kinase 3; LILRA2—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2; LILRA5—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5; PDLIM5—PDZ and LIM domain 5; ARRB1—Arrestin, Beta 1; PAK1—p21 protein (Cdc42/Rac)-activated kinase 1; SOCS2—suppressor of cytokine signaling 2; RHOA—ras homolog gene family, member A; IL-13RA—interleukin 13 receptor, alpha 1; TNFSF13B—tumor necrosis factor (ligand) superfamily, member 13b (BAFF); TNFSF12—tumor necrosis factor (ligand) superfamily, member 12 (APRIL); GSN—gelsolin; SMAD1—SMAD family member 1; VNN1—vanin 1; PPT1—palmitoyl-protein thioesterase 1; SOD2—superoxide dismutase 2, mitochondrial; DAPK1—death-associated protein kinase 1; EVI5—ecotropic viral integration site 5; CCNY—cyclin Y.

Minnie Sarwal - One of the best experts on this subject based on the ideXlab platform.

  • Direction and magnitude of change in TOL group vs. non-TOL and control: Genes with decreased expression in TOL group.
    2015
    Co-Authors: Joseph Pidala, Gregory C. Bloom, Steven Eschrich, Minnie Sarwal, Steve Enkemann, Brian C. Betts, Francisca Beato, Sean Yoder, Claudio Anasetti
    Abstract:

    *TLR4—toll-like receptor 4; TLR8—toll-like receptor 8; PELI2—pellino homolog 2; IRAK3—interleukin-1 receptor-associated kinase 3; LILRA2—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2; LILRA5—leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5; PDLIM5—PDZ and LIM domain 5; ARRB1—Arrestin, Beta 1; PAK1—p21 protein (Cdc42/Rac)-activated kinase 1; SOCS2—suppressor of cytokine signaling 2; RHOA—ras homolog gene family, member A; IL-13RA—interleukin 13 receptor, alpha 1; TNFSF13B—tumor necrosis factor (ligand) superfamily, member 13b (BAFF); TNFSF12—tumor necrosis factor (ligand) superfamily, member 12 (APRIL); GSN—gelsolin; SMAD1—SMAD family member 1; VNN1—vanin 1; PPT1—palmitoyl-protein thioesterase 1; SOD2—superoxide dismutase 2, mitochondrial; DAPK1—death-associated protein kinase 1; EVI5—ecotropic viral integration site 5; CCNY—cyclin Y.